METLIFE INC MET
NYSE · XNYS · stock · Life Insurance
Chart by TradingView
4/9
Piotroski F — financial health
—
Altman Z″ — distress risk
44.7%
Dividend payout · moderate
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.4B | $3.4B | — | — | $28.7B |
| 2024 | $71.0B | $4.4B | — | — | $27.7B |
| 2023 | $2.2B | $1.6B | — | — | $30.3B |
| 2022 | $68.8B | $5.3B | — | — | $30.1B |
| 2021 | $68.7B | $6.9B | — | — | $50.0B |
| 2020 | $67.8B | $5.4B | — | — | $74.8B |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0001099219 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.